免疫检查点抑制剂市场 - 增长、趋势、COVID-19 影响和预测(2022 - 2027 年)

免疫检查点抑制剂市场按抑制剂类型(CTLA-4 抑制剂、PD-1 抑制剂和其他类型的抑制剂)、应用、分销渠道和地理位置进行细分。

免疫检查点抑制剂市场快照

Immune Checkpoint Inhibitors Market Size
Study Period: 2018 - 2026
Base Year: 2021
Fastest Growing Market: Asia Pacific
Largest Market: North America
CAGR: 18 %
Immune Checkpoint Inhibitors Market Major Players

Need a report that reflects how COVID-19 has impacted this market and its growth?

市场概况

在预测期内,研究的免疫检查点抑制剂市场预计将以 18% 的复合年增长率增长。导致市场增长的主要因素是全球各类癌症患病率的急剧上升,以及主要在发达经济体和新兴经济体的各个地理位置的老年人口急剧增加。例如,根据世界卫生组织的报告,癌症是全球死亡的主要原因,估计有 960 万人死亡,肺癌被确定为最常见的死亡原因,2018 年有 176 万人死亡。因此,患者池数量的增加,

报告范围

免疫检查点抑制剂是用于免疫治疗的抗癌药物,可增强免疫反应以检测和靶向癌细胞。与推动免疫检查点抑制剂市场的常规化疗相比,这些药物被广泛接受为晚期癌症的标准治疗方法,因为它们已被证明有效且患者反应积极,副作用发生率较低。

Type of Inhibitors
CTLA-4 Inhibitors
PD-1 Inhibitors
Other Types of Inhibitors
Application
Hodgkin Lymphoma
Kidney Cancers
Melanoma
Non-small Cell Lung Cancer
Other Applications
Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Geography
North America
United states
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle-East and Africa
GCC
South Africa
Rest of Middle-East and Africa
South America
Brazil
Argentina
Rest of South America

Report scope can be customized per your requirements. Click here.

主要市场趋势

PD-1抑制剂细分市场有望在免疫检查点抑制剂市场占据最大市场份额

  • 预计 PD-1 抑制剂部门将在预测期内占最大收入,该部门的主导地位可归因于研究活动量的增加、批准以及这些药物(如 nivolumab 和 pembrolizumab)的处方增加。此外,越来越多地采用派姆单抗 (KEYTRUDA),这是自 2014 年获得批准以来的第一个 PD-1 抑制剂,因为它已被证明可有效治疗多种 FDA 批准的适应症,如黑色素瘤、非小细胞肺癌 (NSCLC)、头颈部鳞状细胞癌细胞癌(HNSCC),以及其他在全球范围内高度流行的疾病,推动了细分市场的增长。与 Yervoy(市场上唯一的 CTLA-4抑制剂产品)药物相关的过敏反应越来越多,预计也将推动该领域的增长。
  • 另一方面,主要参与者为开发低剂量 CTLA-4 抑制剂、其他非 PD-1 和 PD-L1 ICI 药物(如 IDO-1 剂、LAG-3 剂、 TIM-3 代理和 CD47/SIRPα 代理可能会在预测期内推动市场收入。
Immune Checkpoint Inhibitors Market Share

北美有望主导市场

  • 预计北美将在整个预测期内主导整个免疫检查点抑制剂市场。在北美地区,美国占据市场份额。这种主导地位是由于各种慢性疾病的日益流行,如糖尿病、皮肤癌、尿路上皮癌、肺癌,以及在预测期内美国大量婴儿潮一代的存在需要有效的治疗。
  • 例如,根据美国癌症协会对 2020 年的估计,肺癌是第二常见的癌症,导致男性和女性死亡 135,720 人。统计数据还报告说,在美国,大约 13% 的肺癌是小细胞肺癌 (SCLC) 和 84% 的非小细胞肺癌 (NSCLC),预计未来还会继续,从而导致对这些肺癌的需求增加产品推动了该地区的市场。
  • 此外,北美地区市场收入的重要份额可归因于主要关键参与者的存在以及对研发活动的巨额投资,以开发副作用较小的新产品和仿制药,以及政府鼓励减少不断增长的疾病负担的创新,这可能会在预测期内为 ICI 市场的增长提供更多机会。
Immune Checkpoint Inhibitors Market Forecast

竞争格局

PD-1 和 PD-L1 抑制剂市场竞争适度,由几个主要参与者组成。一些公司正在通过采取收购和合并、研究合作等各种策略来扩大其市场地位,而另一些公司则正在投资临床试验,以扩大现有药物对其他适应症的治疗,以解决疾病负担驱动未解决的挑战市场份额。例如,2019 年 6 月,默克公司的 pembrolizumab (KEYTRUDA) 获得美国 FDA 的加速批准,用于治疗在铂类化疗和至少一种可能的其他先前治疗方案中或之后出现疾病进展的转移性 SCLC 患者在预测期内提高市场份额。

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Rising Investments in R&D and Clinical Trials by Bio-pharmaceutical Industries to Develop these Products

      2. 4.2.2 Increased Encouragement by Regulatory Authorities with Favorable Approvals and Special Designations for New Drug Molecules

    3. 4.3 Market Restraints

      1. 4.3.1 Higher Risk of Complications Associated with the Expensive Oncology Treatment

      2. 4.3.2 Challenges in Development with Uncertainty in Regulatory Process and High Costs of Tedious Clinical Trials

    4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 Type of Inhibitors

      1. 5.1.1 CTLA-4 Inhibitors

      2. 5.1.2 PD-1 Inhibitors

      3. 5.1.3 Other Types of Inhibitors

    2. 5.2 Application

      1. 5.2.1 Hodgkin Lymphoma

      2. 5.2.2 Kidney Cancers

      3. 5.2.3 Melanoma

      4. 5.2.4 Non-small Cell Lung Cancer

      5. 5.2.5 Other Applications

    3. 5.3 Distribution Channel

      1. 5.3.1 Hospital Pharmacies

      2. 5.3.2 Retail Pharmacies

      3. 5.3.3 Online Pharmacies

    4. 5.4 Geography

      1. 5.4.1 North America

        1. 5.4.1.1 United states

        2. 5.4.1.2 Canada

        3. 5.4.1.3 Mexico

      2. 5.4.2 Europe

        1. 5.4.2.1 Germany

        2. 5.4.2.2 United Kingdom

        3. 5.4.2.3 France

        4. 5.4.2.4 Italy

        5. 5.4.2.5 Spain

        6. 5.4.2.6 Rest of Europe

      3. 5.4.3 Asia-Pacific

        1. 5.4.3.1 China

        2. 5.4.3.2 Japan

        3. 5.4.3.3 India

        4. 5.4.3.4 Australia

        5. 5.4.3.5 South Korea

        6. 5.4.3.6 Rest of Asia-Pacific

      4. 5.4.4 Middle-East and Africa

        1. 5.4.4.1 GCC

        2. 5.4.4.2 South Africa

        3. 5.4.4.3 Rest of Middle-East and Africa

      5. 5.4.5 South America

        1. 5.4.5.1 Brazil

        2. 5.4.5.2 Argentina

        3. 5.4.5.3 Rest of South America

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 Bristol-Myers Squibb Company

      2. 6.1.2 Merck & Co.

      3. 6.1.3 F. Hoffmann-La Roche AG

      4. 6.1.4 Regeneron Pharmaceuticals Inc.

      5. 6.1.5 AstraZeneca PLC

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Competitive Landscape covers- Business Overview, Financials, Products and Strategies, and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Immune Checkpoint Inhibitors Market market is studied from 2018 - 2026.

The Immune Checkpoint Inhibitors Market is growing at a CAGR of 18% over the next 5 years.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2021.

Bristol Myers Squibb Company, Regeneron Pharmaceuticals Inc, AstraZeneca plc, F. Hoffmann-La Roche AG, Merck & Co Inc are the major companies operating in Immune Checkpoint Inhibitors Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!